{"id":"current-domperidone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL219916","moleculeType":"Small molecule","molecularWeight":"425.92"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking dopamine D2 receptors, Current Domperidone reduces gastrointestinal motility and increases gastric emptying time, alleviating symptoms of gastroparesis and other gastrointestinal disorders.","oneSentence":"Current Domperidone acts as a dopamine D2 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:52.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroparesis"}]},"trialDetails":[{"nctId":"NCT02500108","phase":"","title":"Domperidone and Risk of Sudden Cardiac Death","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-05","conditions":"Parkinson's Disease","enrollment":214962},{"nctId":"NCT02493049","phase":"PHASE2","title":"Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":17},{"nctId":"NCT03806062","phase":"PHASE4","title":"EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-01-02","conditions":"Insufficient Lactation","enrollment":60},{"nctId":"NCT00925457","phase":"","title":"Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Arrhythmias, Cardiac","enrollment":1608}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Current Domperidone","genericName":"Current Domperidone","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Current Domperidone acts as a dopamine D2 receptor antagonist. Used for Gastroparesis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}